Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2017

View Archived Issues

FDA grants orphan drug designation to CK-101 for EGFR mutation-positive NSCLC

MP-0274 begins first-in-human study in HER2-positive solid tumors

New phase I trial evaluates CAR-20/19-T in patients with B-cell malignancies

ReLive trial of Livatag in HCC does not meet primary endpoint

Janssen discontinues further development of JNJ-4178

Primary endpoint not met in SPECTRI study of lampalizumab for geographic atrophy

Editas Medicine initiates clinical natural history study in patients with LCA10

HT-074 shows gastroprotection in experimental models of ulcer

ProQR spins out Amylon Therapeutics

Aldeyra Therapeutics reports results from phase IIa study of ADX-102 in dry eye disease

FDA grants priority review to sNDA for Trisenox

Two novel benzamides show promise for the treatment of schizophrenia

Phase III STATUS study of brexanolone does not meet primary endpoint

Abcellera Biologics, GSK form antibody discovery research collaboration

KemPharm submits amended NDA for Apadaz

NeuroDerm gives update on proposed acquisition by Mitsubishi Tanabe Pharma

Astellas seeks Japanese approval of Linzess for chronic constipation

Onxeo grants Monopar license for Validive

Targovax begins recruiting patients in phase I/II study of ONCOS-102 plus durvalumab

FDA awards fast track designation to SHP-607 to prevent lung disease in very premature infants

NIH announces awards to support development of 3-D human tissue models

Southwest Hospital patents LINC01094-siRNA2 for ischemic stroke

Inotek enters merger agreement with Rocket Pharmaceuticals

Novel mutation found for Niemann-Pick C1 disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...